Storage | Store at 4°C |
Description | The spike protein of COVID-19 is a glycoprotein that helps the virus attach to various surfaces in the built environment, increasing the potential for virus transmission. The best-known vaccines we use are the spike protein vaccines delivered via mRNA. While the role of vaccination in controlling outbreaks is undeniable, the recurring emergence of new variants of Covid-19, such as the Delta and Omicron variants, poses new challenges, particularly their rapid global spread. Within the spike protein, there is a receptor-binding domain, considered a key viral element that allows the coronavirus to dock with target cells. Mutations in the RBD appear in new variants, such as the Delta variant with 2 mutations and the Omicron variant with 15 mutations, posing challenges for pandemic vaccination. Studies have revealed that a large number of antibodies show neutralization activity by targeting the RBD of COVID-19 viruses. The CB6, a human monoclonal antibody obtained from a patient convalescing from COVID-19 has been identified to target the RBD of SARS-CoV-2 with an ability to neutralize the pandemic viruses. This product is designed as a tool for the delivery and expression of anti-RBD (CB6) scFv/CD3 mutant Fc mRNA for research. The product leverages the lipid nanoparticle (LNP) technology platform for simple and efficient delivery of anti-RBD (CB6) scFv/CD3 mutant Fc mRNA to a variety of mammalian cells in vitro and in vivo. The LNPs used are formulated with SM-102, DSPC, cholesterol and DMG-PEG2000 at an optimal molar concentration for a high rate of encapsulation and efficient mRNA delivery. The anti-RBD (CB6) scFv/CD3 mutant Fc in this product is approximately 70 kD and consists of anti-RBD (CB6) scFv (single-chain variable fragment), mutant human Fc and CD3ze signaling domains |
Lipid composition | SM-102/DSPC/Cholesterol/DMG-PEG2000 |
Technical Notes | Work with mRNA-LNP on ice. It is important to minimize the time that the product spends at room temperature; after handling product during experiments, return immediately to ice.Upon receiving product, briefly pulse spin before opening to ensure product is at bottom of container; it is important not to spin for too long as this may rupture mRNA-LNP’s. Do not vortex. mRNA-LNP products should only be handled with certified RNAase-free reagents and consumables; use of filtered pipette tips is highly recommended |
Encoding mRNA | Anti-RBD scFv (CB6)-CD3 mutant Fc |
In Vitro QC (Cell Types) | HEK293S |
Technology Applications | Antibody research |
Required fields are marked with *
×Product Name | Catalog | Lipid composition | Liposome Size | Price |
---|---|---|---|---|
Clipos™ Anti-RBD scFv (CB6)-Fc mRNA Lipid Nanoparticles | CDL23-029-L | SM-102/DSPC/Cholesterol/DMG-PEG2000 | $1980 | |
Clipos™ Anti-RBD scFv (CB6)-Fc mRNA Lipid Nanoparticles | CDL23-078-L | SM-102/DSPC/Cholesterol/DMG-PEG2000 | $1595 | |
Clipos™ Anti-RBD scFv (CB6)-Fc mRNA Lipid Nanoparticles | CDL23-044-L | SM-102/DSPC/Cholesterol/DMG-PEG2000 | $1595 | |
Clipos™ Anti-RBD scFv (CB6)-Fc mRNA Lipid Nanoparticles | CDL23-088-L | SM-102/DSPC/Cholesterol/DMG-PEG2000 | $1980 | |
Clipos™ Anti-RBD scFv (CB6)-Fc mRNA Lipid Nanoparticles | CDL23-020-L | SM-102/DSPC/Cholesterol/DMG-PEG2000 | $1595 | |
Clipos™ Anti-RBD scFv (CB6)-Fc mRNA Lipid Nanoparticles | CDL23-079-L | SM-102/DSPC/Cholesterol/DMG-PEG2000 | $1595 | |
Clipos™ Anti-RBD scFv (CB6)-Fc mRNA Lipid Nanoparticles | CDSNT64 | $1380 | ||
Clipos™ Anti-RBD scFv (CB6)-Fc mRNA Lipid Nanoparticles | CDL23-019-L | SM-102/DSPC/Cholesterol/DMG-PEG2000 | $1695 |
1. Download the template.
2. Enter product information on the template (maximum number of products: 200).
3. Load the file using selector below.
1. Download the template.
2. Enter product information on the template (maximum number of products: 200).
3. Load the file using selector below.